SCHEDULE: Capital World Investors Trims NovoCure Stake to 1.8%

Capital World Investors reported a 1.8% beneficial ownership stake in NovoCure Ltd., holding 2 million shares as of September 30, 2025.

Summary

• Capital World Investors (CWI) filed an Amendment No. 1 to Schedule 13G for NovoCure Ltd.
• CWI beneficially owns 2,000,000 shares of NovoCure Ltd. Common Stock.
• This represents 1.8% of NovoCure Ltd.'s outstanding common stock, based on 111,799,290 shares believed to be outstanding.
• CWI holds sole voting power over 2,000,000 shares and sole dispositive power over 2,000,000 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 4

Explanation: The filing indicates a reduction in Capital World Investors' stake in NovoCure Ltd. to 1.8%, which is generally viewed as a negative signal from a major institutional investor, though they retain a position.

Positives

• Capital World Investors, a significant institutional investor, maintains a position in NovoCure Ltd.

Negatives

• Capital World Investors has reduced its beneficial ownership in NovoCure Ltd. to 1.8%, indicating a decrease from a prior undisclosed stake (as this is Amendment No. 1 and the current percentage is below the 5% threshold for initial 13G filings).

Risks

• A reduction in institutional ownership by a major investment adviser like Capital World Investors may signal a decrease in confidence or a reallocation of assets away from NovoCure Ltd.

Future Outlook

This filing does not contain forward-looking statements or guidance from NovoCure Ltd. or Capital World Investors regarding the issuer's future performance.

Industry Context

This filing primarily reflects an institutional investor's portfolio adjustment rather than broader industry trends or specific competitive dynamics for NovoCure Ltd.

Stakeholder Impact

• Shareholders: May interpret the reduction in institutional ownership as a negative signal, potentially influencing market sentiment and share price.

Key Dates

Recommendation

Capital World Investors has reduced its stake in NovoCure Ltd. to 1.8%, which is a negative signal from a major institutional investor. However, they still maintain a position, suggesting some continued confidence. Without further fundamental company news, a 'hold' recommendation is prudent, advising investors to monitor future developments and other financial reports.

Keywords

NovoCure, Capital World Investors, CWI, institutional ownership, common stock, SEC filing, Schedule 13G, investment adviser, beneficial ownership